Dementia is a frequent complication of Parkinson disease (PD) with a yearly incidence of around 10% of patients with PD. Lewy body pathology is the most important factor in the development of Parkinson disease dementia (PDD) and there is evidence for a synergistic effect with β-amyloid. The clinical phenotype in PDD extends beyond the dysexecutive syndrome that is often present in early PD and encompasses deficits in recognition memory, attention, and visual perception. Sleep disturbances, hallucinations, neuroleptic sensitivity, and fluctuations are often present. This review provides an update on current knowledge of PDD including aspects of epidemiology, pathology, clinical presentation, management, and prognosis.
SantangeloGVitaleCPicilloM. Mild cognitive impairment in newly diagnosed Parkinson’s disease: a longitudinal prospective study. Parkinsonism Relat Disord. 2015;21(10):1219–1226.
2.
AarslandD. Epidemiology of dementia associated with Parkinson's disease. In: EmreM, ed. Cognitive Impairment and Dementia in Parkinson’s Disease. Oxford, UK: Oxford University Press; 2015:5–16.
3.
ReidWGHelyMAMorrisJGLoyCHallidayGM. Dementia in Parkinson’s disease: a 20-year neuropsychological study (Sydney Multicentre Study). J Neurol Neurosurg Psychiatry. 2011;82(9):1033–1037.
4.
ButerTCvan den HoutAMatthewsFELarsenJPBrayneCAarslandD. Dementia and survival in Parkinson disease: a 12-year population study. Neurology. 2008;70(13):1017–1022.
5.
Williams-GrayCHMasonSLEvansJR. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry. 2013;84(11):1258–1264.
6.
AarslandD. Cognitive impairment in Parkinson’s disease and dementia with Lewy bodies. Parkinsonism Relat Disord. 2016;22(suppl 1):S144–S148.
7.
LippaCFDudaJEGrossmanM. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68(11):812–819.
8.
BallardCGarcia-PtacekSvan SteenovenIAarslandD. Spectrum of Lewy body dementias: relationship of Parkinson’s disease dementia to dementia with Lewy bodies. In: EmreM, ed. Cognitive Impairment and Dementia in Parkinson’s Disease. 2nd ed. Oxford, UK: Oxford University Press; 2015:241–260.
9.
AarslandDPerryRBrownALarsenJPBallardC. Neuropathology of dementia in Parkinson’s disease: a prospective, community-based study. Ann Neurol. 2005;58(5):773–776.
10.
HardingAJHallidayGM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol. 2001;102(4):355–363.
11.
TsuboiYDicksonDW. Dementia with Lewy bodies and Parkinson’s disease with dementia: are they different?Parkinsonism Relat Disord. 2005;11(suppl 1):S47–S51.
12.
PosadaIJBenito-LeonJLouisED. Mortality from Parkinson’s disease: a population-based prospective study (NEDICES). Mov Disord. 2011;26(14):2522–2529.
13.
AarslandDZaccaiJBrayneC. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord. 2005;20(10):1255–1263.
14.
OhYSKimJSParkIS. Prevalence and treatment pattern of Parkinson’s disease dementia in Korea. Geriatr Gerontol Int. 2016;16(2):230–236.
15.
RiedelOKlotscheJSpottkeA. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease. J Neurol. 2010;257(7):1073–1082.
16.
WangQZhangZLiLWenHXuQ. Assessment of cognitive impairment in patients with Parkinson’s disease: prevalence and risk factors. Clin Interv Aging. 2014;9:275–281.
17.
Romo-GutierrezDYescasPLopez-LopezMBollMC. Genetic factors associated with dementia in Parkinson’s disease (PD) [in Spanish]. Gac Med Mex. 2015;151(1):110–118.
18.
SteenlandKMacNeilJSealsRLeveyA. Factors affecting survival of patients with neurodegenerative disease. Neuroepidemiology. 2010;35(1):28–35.
19.
IrwinDJWhiteMTToledoJB. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol. 2012;72(4):587–598.
20.
Del TrediciKBraakH. Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson’s disease-related dementia. J Neurol Neurosurg Psychiatry. 2013;84(7):774–783.
21.
HallidayGMLeverenzJBSchneiderJSAdlerCH. The neurobiological basis of cognitive impairment in Parkinson’s disease. Mov Disord. 2014;29(5):634–650.
22.
ParkkinenLPirttilaTAlafuzoffI. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol. 2008;115(4):399–407.
23.
SchneiderJAArvanitakisZYuLBoylePALeurgansSEBennettDA. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain. 2012;135(pt 10):3005–3014.
24.
KempsterPAO’SullivanSSHoltonJLReveszTLeesAJ. Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study. Brain. 2010;133(pt 6):1755–1762.
25.
ComptaYParkkinenLO’SullivanSS. Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important?Brain. 2011;134(pt 5):1493–1505.
26.
ApaydinHAhlskogJEParisiJEBoeveBFDicksonDW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol. 2002;59(1):102–112.
27.
ChoiSAEvidenteVGCavinessJN. Are there differences in cerebral white matter lesion burdens between Parkinson’s disease patients with or without dementia?Acta Neuropathol. 2010;119(1):147–149.
28.
HallidayGHelyMReidWMorrisJ. The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol. 2008;115(4):409–415.
29.
HelyMAReidWGAdenaMAHallidayGMMorrisJG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–844.
30.
BertrandELewandowskaEStepienTSzpakGMPasennikEModzelewskaJ. Amyloid angiopathy in idiopathic Parkinson’s disease. Immunohistochemical and ultrastructural study. Folia Neuropathol. 2008;46(4):255–270.
31.
Malek-AhmadiMKahlonVAdlerCH. Prevalence of hippocampal sclerosis in a clinicopathologically characterized cohort. Clin Exp Med Sci. 2013;1(7):317–327.
32.
LitvanIGoldmanJGTrosterAI. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012;27(3):349–356.
33.
LitvanIAarslandDAdlerCH. MDS Task Force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord. 2011;26(10):1814–1824.
34.
PetersenRC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183–194.
35.
WinbladBPalmerKKivipeltoM. Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256(3):240–246.
36.
PedersenKLarsenJTysnesOAlvesG. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol. 2013;70(5):580–586.
37.
Williams-GrayCHEvansJRGorisA. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132(pt 11):2958–2969.
38.
AarslandD. Cognitive impairment in Parkinson’s disease and dementia with Lewy bodies. Parkinsonism Relat Disord. 2016;22(suppl 1):S144–S148.
39.
GoldmanJGWilliams-GrayCBarkerRADudaJEGalvinJE. The spectrum of cognitive impairment in Lewy body diseases. Mov Disord. 2014;29(5):608–621.
40.
AarslandDBronnickKWilliams-GrayC. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75(12):1062–1069.
41.
GoldmanJGWeisHStebbinsGBernardBGoetzCG. Clinical differences among mild cognitive impairment subtypes in Parkinson’s disease. Mov Disord. 2012;27(9):1129–1136.
42.
JanvinCCLarsenJPAarslandDHugdahlK. Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia. Mov Disord. 2006;21(9):1343–1349.
43.
PagonabarragaJKulisevskyJ. Cognitive impairment and dementia in Parkinson’s disease. Neurobiol Dis. 2012;46(3):590–596.
44.
KehagiaAABarkerRARobbinsTW. Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis. Neurodegener Dis. 2013;11(2):79–92.
45.
Williams-GrayCHFoltynieTBrayneCERobbinsTWBarkerRA. Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain. 2007;130(pt 7):1787–1798.
46.
FoltynieTBrayneCERobbinsTWBarkerRA. The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain. 2004;127(pt 3):550–560.
47.
MuslimovicDPostBSpeelmanJDSchmandB. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005;65(8):1239–1245.
48.
ChristopherLMarrasCDuff-CanningS. Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson’s disease with mild cognitive impairment. Brain. 2014;137(pt 2):565–575.
49.
LevyGJacobsDMTangMX. Memory and executive function impairment predict dementia in Parkinson’s disease. Mov Disord. 2002;17(6):1221–1226.
50.
JanvinCCAarslandDLarsenJP. Cognitive predictors of dementia in Parkinson’s disease: a community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol. 2005;18(3):149–154.
51.
BiundoRWeisLFacchiniS. Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia. Parkinsonism Relat Disord. 2014;20(4):394–399.
BallardCGAarslandDMcKeithI. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology. 2002;59(11):1714–1720.
54.
WalkerMPAyreGACummingsJL. The clinician assessment of fluctuation and the one day fluctuation assessment scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry. 2000;177:252–256.
55.
BronnickKEhrtUEmreM. Attentional deficits affect activities of daily living in dementia-associated with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2006;77(10):1136–1142.
56.
CostaAMonacoMZabberoniS. Free and cued recall memory in Parkinson’s disease associated with amnestic mild cognitive impairment. PLoS One. 2014;9(1):e86233.
57.
LevinBELlabreMMReismanS. Visuospatial impairment in Parkinson’s disease. Neurology. 1991;41(3):365–369.
58.
KidaYTachibanaHTakedaMYoshikawaHOkitaT. Recognition memory for unfamiliar faces in Parkinson’s disease: behavioral and electrophysiologic measures. Parkinsonism Relat Disord. 2007;13(3):157–164.
59.
ZgaljardicDJFoldiNSBorodJC. Cognitive and behavioral dysfunction in Parkinson’s disease: neurochemical and clinicopathological contributions. J Neural Transm (Vienna). 2004;111(10-11):1287–1301.
60.
KehagiaAABarkerRARobbinsTW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol. 2010;9(12):1200–1213.
61.
BarnesJDavidAS. Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry. 2001;70(6):727–733.
62.
FenelonGMahieuxFHuonRZieglerM. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain. 2000;123(pt 4):733–745.
63.
WilliamsDRLeesAJ. Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol. 2005;4(10):605–610.
64.
InzelbergRSchecthmanEPaleacuD. Onset and progression of disease in familial and sporadic Parkinson’s disease. Am J Med Genet A. 2004;124A(3):255–258.
65.
Committee HGN. PARK2. In: EMBL Outstation—Hinxton EBI, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, CB10 1SD, UK Web site. www.genenames.org. Accessed September 09, 2015.
66.
KimWSKagedalKHallidayGM. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther. 2014;6(5):73.
HaugarvollKRademakersRKachergusJM. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology. 2008;70(16 pt 2):1456–1460.
69.
HealyDGFalchiMO’SullivanSS. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol. 2008;7(7):583–590.
NombelaCRoweJBWinder-RhodesSE. Genetic impact on cognition and brain function in newly diagnosed Parkinson’s disease: ICICLE-PD study. Brain. 2014;137(pt 10):2743–2758.
72.
EerolaJLaunesJHellstromOTienariPJ. Apolipoprotein E (APOE), PARKIN and catechol-O-methyltransferase (COMT) genes and susceptibility to sporadic Parkinson’s disease in Finland. Neurosci Lett. 2002;330(3):296–298.
73.
Apolipoprotein E genotype in familial Parkinson’s disease. The French Parkinson’s Disease Genetics Study Group. J Neurol Neurosurg Psychiatry. 1997;63(3):394–395.
74.
LopezMGuerreroJYescasP. Apolipoprotein E epsilon4 allele is associated with Parkinson disease risk in a Mexican Mestizo population. Mov Disord. 2007;22(3):417–420.
75.
Serrano-PozoAQianJMonsellSEBetenskyRAHymanBT. APOEepsilon2 is associated with milder clinical and pathological Alzheimer disease. Ann Neurol. 2015;77(6):917–929.
76.
ParsianARacetteBGoldsmithLJPerlmutterJS. Parkinson’s disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics. 2002;79(3):458–461.
77.
MarderKMaestreGCoteL. The apolipoprotein epsilon 4 allele in Parkinson’s disease with and without dementia. Neurology. 1994;44(7):1330–1331.
78.
TsuangDLeverenzJBLopezOL. APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol. 2013;70(2):223–228.
79.
HuangXChenPKauferDITrösterAIPooleC. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol. 2006;63(2):189–193.
80.
de LauLMSchipperCMHofmanAKoudstaalPJBretelerMM. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol. 2005;62(8):1265–1269.
81.
GorisAWilliams-GrayCHClarkGR. Tau and α-synuclein in susceptibility to, and dementia in, Parkinson’s disease. Ann Neurol. 2007;62(2):145–153.
82.
Winder-RhodesSEEvansJRBanM. Glucocerebrosidase mutations influence the natural history of Parkinson’s disease in a community-based incident cohort. Brain. 2013;136(2):392–399.
83.
WongKSidranskyEVermaA. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab. 2004;82(3):192–207.
84.
Goker-AlpanOSchiffmannRLaMarcaMENussbaumRLMcInerney-LeoASidranskyE. Parkinsonism among Gaucher disease carriers. J Med Genet. 2004;41(12):937–940.
85.
BrasJGuerreiroRDarwentL. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet. 2014;23(23):6139–6146.
86.
GuerreiroREscott-PriceVDarwentL. Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson’s and Alzheimer’s diseases. Neurobiol Aging. 2016;38:214.e217–214.e210.
87.
ChungSJJungYHongM. Alzheimer’s disease and Parkinson’s disease genome-wide association study top hits and risk of Parkinson’s disease in Korean population. Neurobiol Aging. 2013;34(11):2695.e2691–2695.e2697.
88.
WangYQTangBSYangY. Relationship between Alzheimer’s disease GWAS-linked top hits and risk of Parkinson’s disease with or without cognitive decline: a Chinese population-based study. Neurobiol Aging. 2016;39:217.e219–217.e211.
89.
GaoJHuangXParkYHollenbeckAChenH. An exploratory study on CLU, CR1 and PICALM and Parkinson disease. PLoS One. 2011;6(8):e24211.
90.
EmreMAarslandDBrownR. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22(12):1689–1707; quiz 1837.
91.
ZadikoffCFoxSHTang-WaiDF. A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson’s disease. Mov Disord. 2008;23(2):297–299.
92.
NazemSSiderowfADDudaJE. Montreal cognitive assessment performance in patients with Parkinson’s disease with “normal” global cognition according to mini-mental state examination score. J Am Geriatr Soc. 2009;57(2):304–308.
93.
BurdickDJCholertonBWatsonGS. People with Parkinson’s disease and normal MMSE score have a broad range of cognitive performance. Mov Disord. 2014;29(10):1258–1264.
94.
ChouKLAmickMMBrandtJ. A recommended scale for cognitive screening in clinical trials of Parkinson’s disease. Mov Disord. 2010;25(15):2501–2507.
95.
van SteenovenIAarslandDHurtigH. Conversion between Mini-Mental State Examination, Montreal Cognitive Assessment, and dementia rating scale-2 scores in Parkinson’s disease. Mov Disord. 2014;29(14):1809–1815.
ChristopherLStrafellaAP. Neuroimaging of brain changes associated with cognitive impairment in Parkinson’s disease. J Neuropsychol. 2013;7(2):225–240.
98.
SongSKLeeJEParkHJSohnYHLeeJDLeePH. The pattern of cortical atrophy in patients with Parkinson’s disease according to cognitive status. Mov Disord. 2011;26(2):289–296.
HuangCMattisPPerrineKBrownNDhawanVEidelbergD. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology. 2008;70(16 pt 2):1470–1477.
101.
PetrouMDwamenaBAFoersterBR. Amyloid deposition in Parkinson’s disease and cognitive impairment: a systematic review. Mov Disord. 2015;30(7):928–935.
102.
BonanniLThomasATiraboschiPPerfettiBVaraneseSOnofrjM. EEG comparisons in early Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease with dementia patients with a 2-year follow-up. Brain. 2008;131(pt 3):690–705.
103.
AkbarUFriedmanJH. Recognition and treatment of neuropsychiatric disturbances in Parkinson’s disease. Expert Rev Neurother. 2015;15(9):1053–1065.
104.
DavidFJRobichaudJALeurgansSE. Exercise improves cognition in Parkinson’s disease: the PRET-PD randomized, clinical trial. Mov Disord. 2015;30(12):1657–1663.
105.
PeñaJIbarretxe-BilbaoNGarcía-GorostiagaIGomez-BeldarrainMADíez-CirardaMOjedaN. Improving functional disability and cognition in Parkinson disease: randomized controlled trial. Neurology. 20142014;83(23):2167–2174.
106.
ArendtTBiglVArendtATennstedtA. Loss of neurons in the nucleus basalis of Meynert in Alzheimer’s disease, paralysis agitans and Korsakoff’s disease. Acta Neuropathol. 1983;61(2):101–108.
107.
BohnenNIKauferDIIvancoLS. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol. 2003;60(12):1745–1748.
108.
WangHFYuJTTangSW. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol. 2015;86(2):135–143.
109.
McKeithIDel SerTSpanoP. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031–2036.
110.
EmreMAarslandDAlbaneseA. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351(24):2509–2518.
111.
AarslandDLaakeKLarsenJPJanvinC. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002;72(6):708–712.
112.
RavinaBPuttMSiderowfA. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurgery Psychiatry. 2005;76(7):934–939.
113.
LeroiIBrandtJReichSG. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriatr Psychiatry. 2004;19(1):1–8.
114.
MoriEIkedaMKosakaK, on behalf of the Donepezil DLBSI. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72(1):41–52.
115.
DuboisBTolosaEKatzenschlagerR. Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012;27(10):1230–1238.
116.
AarslandDBallardCWalkerZ. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613–618.
117.
EmreMTsolakiMBonuccelliU. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–977.
118.
LeroiIOvershottRByrneEJDanielEBurnsA. Randomized controlled trial of memantine in dementia associated with Parkinson’s disease. Mov Disord. 2009;24(8):1217–1221.
119.
LitvinenkoIVOdinakMMMogil’nayaVIEmelinAY. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson’s disease (an open controlled trial). Neurosci Behav Physiol. 2008;38(9):937–945.
120.
BhasinMRowanEEdwardsKMcKeithI. Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis. Int J Geriatr Psychiatry. 2007;22(9):890–895.
121.
RolinskiMFoxCMaidmentIMcShaneR. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012;3:CD006504.
122.
MamikonyanEXieSXMelvinEWeintraubD. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Mov Disord. 2015;30(7):912–918.
123.
MinettTSThomasAWilkinsonLM. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia. Int J Geriatr Psychiatry. 2003;18(11):988–993.
124.
O’BrienJTBurnsA; BAP Dementia Consensus Group. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol (Oxf). 2011;25(8):997–1019.
125.
AarslandDPerryRLarsenJP. Neuroleptic sensitivity in Parkinson’s disease and parkinsonian dementias. J Clin Psychiatry. 2005;66(5):633–637.
126.
Low-dose clozapine for the treatment of drug-induced psychosis in parkinson’s disease. N Engl J Med. 1999;340(10):757–763.
127.
OndoWGTintnerRDat VoungKLaiDRingholzG. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord. 2005;20(8):958–963.
128.
FernandezHHOkunMSRodriguezRL. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci. 2009;119(12):2196–2205.
129.
RabeyJMProkhorovTMiniovitzADobronevskyEKleinC. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord. 2007;22(3):313–318.
130.
ShotboltPSamuelMFoxCDavidAS. A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease. Neuropsychiatr Dis Treat. 2009;5:327–332.
131.
CummingsJIsaacsonSMillsR. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–540.
132.
MolloySMcKeithIGO’BrienJTBurnDJ. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2005;76(9):1200–1203.
133.
SternYTangMXJacobsDM. Prospective comparative study of the evolution of probable Alzheimer’s disease and Parkinson’s disease dementia. J Int Neuropsychol Soc. 1998;4(3):279–284.
134.
OhESLeeJHJeongSHSohnEHLeeAY. Comparisons of cognitive deterioration rates by dementia subtype. Arch Gerontol Geriatr. 2011;53(3):320–322.
135.
KulisevskyJPagonabarragaJ. Cognitive impairment in Parkinson’s disease: tools for diagnosis and assessment. Mov Disord. 2009;24(8):1103–1110.
136.
AarslandDAndersenKLarsenJP. The rate of cognitive decline in Parkinson disease. Arch Neurol. 2004;61(12):1906–1911.
137.
Garcia-PtacekSFarahmandBKareholtIReligaDCuadradoMLEriksdotterM. Mortality risk after dementia diagnosis by dementia type and underlying factors: a cohort of 15,209 patients based on the Swedish dementia registry. J Alzheimers Dis. 2014;41(2):467–477.
138.
Garcia-PtacekSKareholtIFarahmandBCuadradoMLReligaDEriksdotterM. Body-mass index and mortality in incident dementia: a cohort study on 11,398 patients from SveDem, the Swedish Dementia Registry. J Am Med Dir Assoc. 2014;15(6):447.e441-e447.
